Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma
- 17 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurosurgical Review
- Vol. 44 (6), 3335-3348
- https://doi.org/10.1007/s10143-021-01492-7
Abstract
Epithelioid glioblastoma is a new variant of glioblastoma that has been recently recognized in the 2016 WHO classification of brain tumors. Given the rarity of epithelioid glioblastoma, the clinical characteristics, pathological features, radiological findings, and treatment outcomes are still not well characterized. Therefore, we identified eighty-four epithelioid glioblastoma cases to investigate these characteristics and identify the possible prognostic factors of survival. There were 55 male and 29 female patients with a mean age of 33.6 years. Headache (77.3%) was the most common clinical symptom, and other common symptoms included nausea or vomiting (34%), dizziness (20.5%), seizures (13.6%), and limb weakness (13.6%). Most lesions (88.1%) were located in cerebral lobes, especially in the frontal lobe and temporal lobe. One hundred percent of the patients were IDH1 wild-type (75/75) and INI-1 positive (58/58), and 57.3% (47/82) of patients harbored BRAFV600E mutation. The median overall survival (OS) of all patients was 10.5 months. Patients who received chemotherapy (p = 0.006) or radiotherapy (p = 0.022) had a longer survival than patients who did not. In addition, the K-M curve showed that the BRAFV600E mutation status was not associated with survival (p = 0.724). These findings may assist clinicians with better understanding and management of epithelioid glioblastoma.Keywords
Funding Information
- Department of Science and Technology of Sichuan Province (NO. 2017SZ0006)
This publication has 65 references indexed in Scilit:
- 1p/19q testing has no significance in the workup of glioblastomasNeuropathology and Applied Neurobiology, 2013
- The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-AnalysisPLOS ONE, 2012
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastomaNature, 2012
- Epithelioid Versus Rhabdoid Glioblastomas Are Distinguished by Monosomy 22 and Immunohistochemical Expression of INI-1 but not Claudin 6The American Journal of Surgical Pathology, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcomaCancer, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaThe New England Journal of Medicine, 2005
- Mutations of the BRAF gene in human cancerNature, 2002
- Spontaneous Intracranial Hemorrhage Caused by Brain TumorNeurosurgery, 1982